AR and neoplasm: To test the impact of AR-V-expressing tumor cells on the therapeutic response of heterogeneous CRPC, we developed subcutaneous xenografts with a 90%/10% mixture of R1-AD1/R1-D567 cells and treated mice with a combination of castration and enzalutamide (Figure 1C).